Clinical Trial Update: Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk retinal detachment patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Proliferative Vitreoretinopathy
• Rhegmatogenous Retinal Detachment

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Heparin (unfractionated heparin)

Snippet

Sponsor: Universitätsklinikum Köln | Conditions: Rhegmatogenous Retinal Detachment, High-risk for Proliferative Vitreoretinopathy (PVR) | Phase 3 | Status: COMPLETED